

# Basic Clinical Pharmacokinetics

**Michael E. Winter, Pharm.D.**

Professor of Clinical Pharmacy

School of Pharmacy

University of California, San Francisco

*and*

Director

Clinical Pharmacokinetics Consultation Service

University of California Hospitals and Clinics

San Francisco, California

*Edited by:*

**Mary Anne Koda-Kimble, Pharm.D.**

Professor of Clinical Pharmacy

Chairwoman, Division of Clinical Pharmacy

School of Pharmacy

University of California

San Francisco, California

Applied Therapeutics, Inc.  
Vancouver, WA

Applied Therapeutics, Inc.  
Post Office Box 5077  
Vancouver, Washington 98668-5077  
(206) 253-7123

© Copyright 1994 by Applied Therapeutics, Inc.  
Printed in the United States of America

All rights reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise now known or by any future method without prior written permission from the publisher.

Library of Congress Catalog Card Number 94-70212  
ISBN 0-915486-22-9

First Printing, July 1994  
Second Printing, August 1994

sorption characteristics of the administered chemical form (e.g., salt, ester), the dosage form (e.g., tablet, capsule), the route of administration, the stability of the active ingredient in the gastrointestinal tract, and, the extent of drug metabolism before reaching the systemic circulation. Drugs can be metabolized by gastrointestinal bacteria, by the gastrointestinal mucosa, and by the liver before reaching the systemic circulation.

To calculate the amount of drug absorbed, the administered dose should be multiplied by a bioavailability factor, which is usually represented by the letter "F." For example, the bioavailability of digoxin (Lanoxin) is estimated to be 0.7 for orally administered tablets.<sup>1,2</sup> This means that if 250 µg (0.25 mg) of digoxin is given orally, the effective or absorbed dose can be calculated by multiplying the administered dose by F:

$$\text{Amount of Drug Absorbed or Reaching Systemic Circulation} = (F)(\text{Dose})$$

Eq. 1

$$= (0.7)(250 \mu\text{g})$$

$$= 175 \mu\text{g}$$

It should be emphasized that this factor does not take into consideration the *rate* of drug absorption; it only estimates the *extent* of absorption. Although the rate of absorption can be important when rapid onset of pharmacological effects is required, it is not usually important when a drug is administered chronically. The rate of absorption is important only when it is so slow that it limits the absolute bioavailability of the drug, or when it is so rapid that too much drug is absorbed. The former occasionally occurs with some sustained-release preparations.<sup>3,4</sup>

### *Dosage Form*

As noted earlier, bioavailability can vary among different formulations and dosage forms of a drug. For example, digoxin elixir has a bio-



$$\text{Dose of New Dosage Form} = \frac{\text{Amount of Drug Absorbed From Current Dosage Form}}{F \text{ of New Dosage Form}}$$

Eq. 2

For example, if a patient who has been receiving digoxin 250 µg (0.25 mg) in the tablet dosage form, needs to receive digoxin elixir instead, an equivalent dose of the elixir would be calculated as follows:

$$\begin{aligned} \text{Dose of Elixir} &= \frac{175 \mu\text{g}}{0.77} \\ &= 227 \mu\text{g} \end{aligned}$$

If the soft gelatin capsules of digoxin were to be administered, the bioavailability or F of the new dosage form would have been 1.0 and the equivalent dose would have been 175 µg.

The bioavailability of parenterally-administered drugs usually is considered to be 1.0. Drugs which are administered as inactive precursors that must then be converted to an active product are an exception to this rule. If some of the inactive precursor is excreted or eliminated from the body *before* it can be converted to the active compound, the bioavailability will be <1.0. For example, parenteral chloramphenicol is given as the succinate ester, and this chloramphenicol ester must be hydrolyzed to the active compound. The bioavailability of the parenterally-administered chloramphenicol succinate ranges from 55% to 95%, because from 5% to 45% of the chloramphenicol ester is eliminated renally before it can be converted to the active compound.<sup>7</sup>



amount of drug absorbed from a salt  
follows:

$$\frac{\text{Amount of Drug Absorbed or}}{\text{Amount Reaching the Systemic Circulation}} = (S)(F)(\text{Dose})$$

Eq. 3

The "S" factor should be included in all bioavailability equations as a constant reminder of its importance in assessing bioavailability of the active drug form. When a drug is administered in its parent or active form, the "S" for that drug is 1.0.

Equation 2 can now be expanded to consider the salt factor as well as the bioavailability when calculating the dose of a new dosage form:

$$\frac{\text{Dose of New}}{\text{Dosage Form}} = \frac{\text{Amount of Drug Absorbed}}{\text{From Current Dosage Form}} \div \frac{(S)(F) \text{ of New Dosage Form}}{1}$$

Eq. 4

Aminophylline is an excellent example of this principle. (See Figure 1.) Aminophylline is the ethylenediamine salt of the pharmacologically-active moiety, theophylline. Eighty to eighty-five percent (by weight) of this salt is theophylline, so that the "S" for aminophylline is approximately 0.8. Uncoated aminophylline tablets are considered to be completely (100%) bioavailable; the bioavailability factor (F) for this dosage form is, therefore, 1.0. It is important to consider the salt form in determining the amount of theophylline absorbed from an aminophylline tab

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.